News | Cancer News & Info

top of page

Search

ASCO24: Osimertinib Set to Become the New Standard of Care for Locally Advanced EGFR-Mutated NSCLC

ASCO24: Osimertinib Set to Become the New Standard of Care for Locally Advanced EGFR-Mutated NSCLC

ASCO24: Osimertinib Set to Become the New Standard of Care for Locally Advanced EGFR-Mutated NSCLC

Sara Fagerlie, PhD, CHCP

Jun 10, 20242 min read

Superior Response with Asciminib vs SOC TKIs in Newly Diagnosed CML

Superior Response with Asciminib vs SOC TKIs in Newly Diagnosed CML

Superior Response with Asciminib vs SOC TKIs in Newly Diagnosed CML

Sara Fagerlie, PhD, CHCP

Jun 2, 20242 min read

FDA Grants Full Approval to Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer

FDA Grants Full Approval to Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer

FDA Grants Full Approval to Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer

Sara Fagerlie, PhD, CHCP

Apr 30, 20241 min read

bottom of page